Influence of transporter polymorphisms on digoxin serum concentrations: a systematic review and meta-analysis [0.03%]
药物转运多态性对洋地黄毒苷血药浓度影响的系统评价和meta分析研究
Xin Yee Low,Muhammad Danish Badrul Hisham,Jia Wen Lee et al.
Xin Yee Low et al.
Introduction: Polymorphisms in transporter (P-gp, OATP) genes affect digoxin pharmacokinetics and are crucial for predicting toxicity due to its narrow therapeutic index. However, evidence regarding their effects on digox...
Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients: prevalence of variants with decreased activity and chemotherapy outcomes [0.03%]
癌症患者二氢嘧啶脱氢酶(DPYD)基因检测与氟尿嘧啶类药物治疗及预后关系研究
Christopher Rosso,Michela Febbraro,Ioannis A Voutsadakis
Christopher Rosso
Background: Fluoropyrimidines are among the most useful drugs in oncology with an established record of efficacy and safety. A minority of oncology patients bear genetic variants with reduced activity of the main enzyme c...
Exploring the potential of pharmacogenetic testing in Alabama Veterans diagnosed with major depressive disorder [0.03%]
探索药理基因组检测在阿拉巴马州退伍军人重度抑郁障碍诊断中的潜在作用
Courtney Watts Alexander,Tyler Long,Courtney Gamston et al.
Courtney Watts Alexander et al.
Aims: Major depressive disorder (MDD) is highly prevalent among Veterans, who often experience inadequate response to first-line antidepressants. Pharmacogenetic testing may improve treatment selection by identifying gene...
Correction [0.03%]
改正clidataworks补充：修正/纠正
Published Erratum
Pharmacogenomics. 2026 Feb 16:1. DOI:10.1080/14622416.2026.2632485 2026
The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis [0.03%]
NAT2基因变异在抗结核药物引起肝损伤中的作用：一项meta分析
Vrunda Tavkar,Ankita Goyal,Vishal Chopra et al.
Vrunda Tavkar et al.
Background: Anti-tuberculosis drug-induced liver injury (AT-DILI) is one of the significant adverse effects of first-line tuberculosis therapy, frequently resulting in treatment discontinuation. Genetic polymorphisms in N...
Importance of genetic ancestry in pharmacogenomics for precision medicine [0.03%]
基因祖先在精准医学药物基因组学中的重要性研究进展
Rasika Venkatesh,Karl Keat,Maxwell Salvatore et al.
Rasika Venkatesh et al.
Genetic ancestry refers to an individual's biogeographical origins inferred from correlated allele frequencies shared with individuals from similar ancestral regions. Understanding the complexities of genetic ancestry has proven beneficial ...
Identification and functional characterization of 11 novel CYP2C19 variants in the Chinese Han population [0.03%]
汉人中11个新型CYP2C19变异的鉴定和功能表征
Qinrong Lin,Wenfeng Xu,Qiaoling Zhang et al.
Qinrong Lin et al.
Introduction: The cytochrome P450 2C19 (CYP2C19) enzyme plays a critical role in the metabolism of several clinically important drugs, but the genetic polymorphisms of CYP2C19 have been partially characterized in the Chin...
UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients [0.03%]
乌德连蛋白1A6变异与地拉罗司导致的不良反应：伊朗地区地中海贫血患者的并发症特异性分析
Malihe Najaflu,Ellis J Neufeld,Marjan Mansourian et al.
Malihe Najaflu et al.
Aims: Deferiprone, an iron chelator, causes variable adverse drug reactions (ADRs) in β-thalassemia patients, suggesting a role for pharmacogenetic factors. To address the lack of comprehensive pharmacogenetic data, this...
Provider perceptions on the clinical utility of pharmacogenomics testing: views of psychiatry physicians from an academic center [0.03%]
学术中心精神病医师对药物基因组检测临床效用的看法
Andrew Sulaiman,Cyrus Gilbert,James M Stevenson et al.
Andrew Sulaiman et al.
Provider attitudes on the clinical applicability of pharmacogenomics (PGx) are variable. We investigated psychiatry provider perspectives on PGx testing to gauge familiarity, implementation barriers/facilitators, and educational gaps within...